SAN FRANCISCO, Feb. 25, 2020 /PRNewswire/ -- The global cardiac rhythm management devices market size is anticipated to reach USD 34.1 billion by 2027, as per a new report by Grand View Research, Inc., registering a CAGR of 6.8% over the forecast period. The market has shown constant growth in the adoption of cardiac rhythm management (CRM) devices owing to increasing prevalence of cardiovascular disorders. Cardiovascular Diseases (CVDs) are one of the main causes of mortality in the U.S.; one-fourth of all deaths in the country are the result of CVDs. Stroke and ischemic heart disease account for more than 80% of all cardiac deaths worldwide. According to CDC in 2017, CVDs were responsible for about 800,000 lives lost in the U.S.

Key suggestions from the report:

• By product, defibrillators for cardiac rhythm management held the dominant share due to their high acceptance in countries such as U.S., China, and India
• Implantable cardioverter defibrillators formed the largest sub-segment by product in 2019 owing to better patient outcome
• Among external defibrillators for cardiac rhythm management, the manual variants generated the highest revenue owing to associated benefits such as converting arrhythmia or tachycardia to a normal heartbeat
• Physio-Control, Inc. (Stryker); Medtronic; St. Jude Medical; and Boston Scientific Corporation are some of the major participants in CRM devices market due to their extensive product offerings and strong regional presence.

Read 100 page research report with ToC on "Cardiac Rhythm Management Devices Market Size, Share & Trends Analysis Report By Product (Pacemakers, Defibrillators, CRT), By Region, And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/cardiac-rhythm-management-devices-industry/

Reimbursement policies, such as those introduced by the U.S. Medicare system, are among the major factors boosting the CRM market. Medical device companies now provide new product platforms that are covered under reimbursement programs, which benefit cardiac patients. Reimbursement can be availed for devices such as biventricular pacemakers, single chamber, and dual chamber.

Revolutionary technological progresses are rapidly transforming the CRM devices market, offering lucrative growth potentials. Increase in R&D expenditure and new product launches by leading firms have further fueled market growth. For instance, Biotronik's Rivacor and Acticor, both high voltage CRM devices for cardiac arrhythmia treatment, gained FDA approval in March 2019. In May that year, Medtronic launched the CareLink SmartSync Device Manager.

Some of the major players in the market for cardiac rhythm management solutions are Physio-Control, Inc. (Stryker); Medtronic; St. Jude Medical; and Boston Scientific Corporation, which account for a significant share in the market owing to their extensive product offerings. Industry players are striving to gain market penetration and adopting strategies such as new product launch and M&As. In March 2019, Zoll acquired Golden Hour Data Systems to optimize its operations with a complete suite of business solutions.

Grand View Research has segmented the global cardiac rhythm management device market on the basis of product and region:

• CRM Devices Product Outlook (Revenue, USD Million, 2016 - 2027)
• Pacemakers
• Implantable
• External
• Defibrillators
• Implantable Cardioverter Defibrillators (ICD)
• S-ICD
• T-ICD
• External Defibrillator
• Manual External Defibrillator
• Automatic External Defibrillator
• Wearable Cardioverter Defibrillator
• Cardiac Resynchronization Therapy (CRT)
• CRT-Defibrillator
• CRT-Pacemakers
• CRM Devices Regional Outlook (Revenue, USD Million, 2016 - 2027)
• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• South Africa
• Saudi Arabia

Find more research reports on Medical Devices Industry, by Grand View Research:

• Surgical Navigation Systems Market – Growing geriatric population along with rising prevalence of brain cancer, orthopedic degenerative and ENT among other target disorders and diseases is expected to propel the demand for surgical navigation systems (SNSs).
• Microfluidics Market – Demand for microfluidic-based devices is expected to surge owing to introduction of novel technologies such as digital microfluidics. These techniques allow on-chip biochemical analysis, thereby driving adoption.
• Contrast Media Market – Increasing burden of chronic diseases is driving the demand for diagnostic imaging procedures which are anticipated to fuel the contrast agents market growth.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com 
Web: https://www.grandviewresearch.com 
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

SOURCE Grand View Research, Inc.